Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,724 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,600 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05020275 | Resistance to the Tyrosine Kinase Inhibitor Osimertinib and Pharmacokinetics in Non-small Cell Lung Cancer(RESISTYR) | active not recruiting | — | 60 | Rennes University HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06685133 | Prospective Evaluation of the Tool-in-lesion Technology of the Galaxy System in Routine Clinical Practice(Match 2) | active not recruiting | — | 50 | Noah MedicalINDUSTRY |
| 1 |
| Aug 15, 2025 |
| clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | active not recruiting | Phase 2 | 132 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05049044 | Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE)(OBSTINATE) | active not recruiting | — | 413 | Groupe Francais De Pneumo-CancerologieOTHER | 1 | Aug 4, 2025 | clinicaltrials |
| NCT05078931 | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | active not recruiting | Phase 2 | 35 | Shanghai Chest HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT03753685 | X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | active not recruiting | Phase 2 | 27 | Fudan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT05894889 | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | active not recruiting | Phase 2 | 70 | Peking UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT03670056 | Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy | active not recruiting | Phase 2 | 25 | Yale UniversityOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT05195619 | Personalized DC Vaccines in Non Small Cell Lung Cancer | active not recruiting | Phase 1 | 16 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05224141 | Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) | active not recruiting | Phase 3 | 460 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Jul 8, 2025 | clinicaltrials |
| NCT02284308 | Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy(ELDAPT) | active not recruiting | — | 180 | Maastricht Radiation OncologyOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05919147 | The Neuroendocrine Effects of Pioglitazone in Patients With Cancer and Cachexia(TRACE-1) | active not recruiting | Phase 2 | 24 | Pennington Biomedical Research CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT05943795 | A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma | active not recruiting | Phase 3 | 589 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04175769 | A Nutritional Supplement to Support People With Non-small Cell Lung Cancer | active not recruiting | N/A | 9 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT05116462 | Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | active not recruiting | Phase 3 | 506 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04676477 | HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 246 | Daiichi SankyoINDUSTRY | 4 | Jun 22, 2025 | clinicaltrials |
| NCT05607550 | Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT) | active not recruiting | Phase 3 | 398 | ArriVent BioPharma, Inc.INDUSTRY | 19 | Jun 22, 2025 | clinicaltrials |
| NCT07024862 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy | active not recruiting | — | 100 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT04533451 | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 101 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04027647 | Phase 2 Study of Dacomitinib in NSCLC | active not recruiting | Phase 2 | 118 | National Cancer Centre, SingaporeOTHER | 5 | Jun 12, 2025 | clinicaltrials |
| NCT05319574 | SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer(SACTION01) | active not recruiting | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03800134 | A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer(AEGEAN) | active not recruiting | Phase 3 | 825 | AstraZenecaINDUSTRY | 28 | Jun 11, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT01130285 | Validation of a Multi-gene Test for Lung Cancer Risk | active not recruiting | — | 403 | University of Toledo Health Science CampusOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02041845 | Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer(THORA) | active not recruiting | N/A | 177 | Norwegian University of Science and TechnologyOTHER | 3 | Jun 6, 2025 | clinicaltrials |
| NCT07005999 | Interventional Ablation for Early-stage Lung Cancer | active not recruiting | — | 656 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT07002788 | Comparison Paravertebral and Serratus Anterior Plane Block in Video-assisted Thoracoscopic Surgery. | active not recruiting | N/A | 122 | Hacettepe UniversityOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT03390686 | A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | active not recruiting | Phase 3 | 650 | Prestige Biopharma LimitedINDUSTRY | 17 | May 31, 2025 | clinicaltrials |
| NCT03970746 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | active not recruiting | Phase 1 / Phase 2 | 73 | PDC*line Pharma SASINDUSTRY | 5 | May 29, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT04043195 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC(NSCLC) | active not recruiting | Phase 1 / Phase 2 | 30 | Hatim HusainOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06876402 | Gene Molecular Alterations as Disease Prognostic Markers in Patients With Non-small Cell Lung Cancer (NSCLC)(GEMA-proN) | active not recruiting | — | 367 | Hellenic Cooperative Oncology GroupOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT05441956 | TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 | 198 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05955391 | TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 164 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06082635 | TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 321 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT05742204 | Plasma Proteomic Biomarkers for Early Diagnosis of Lung Cancer | active not recruiting | — | 3,700 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06056128 | Confirmation of Accuracy of the Tool-in-lesion Technology (TiLT) of the Galaxy System With Integrated TOMO Technology(TiLT) | active not recruiting | N/A | 25 | Noah MedicalINDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06942845 | Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre Study | active not recruiting | — | 300 | Xinghua ChengOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT06557187 | Hippocampus-Avoidance Whole-Brain Radiation Therapy With Simultaneous Integrated Boost for BMs of NSCLC | active not recruiting | N/A | 40 | Yatian LiuOTHER | 1 | Apr 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 15, 2025source: clinicaltrials